Related Experiment Video
Updated: Jan 23, 2026

Paper-based Devices for Isolation and Characterization of Extracellular Vesicles
Published on: April 3, 2015
Red blood cell extracellular vesicles as robust carriers of RNA-based therapeutics
Chanh Tin Pham1, Xin Zhang1, Austin Lam1
1Department of Biomedical Sciences, College of Veterinary Medicine and Life Sciences, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong.
Abstract:
One of the major challenges of RNA-based therapeutics is the method for delivery of RNA molecules. In a recent article (Nat Commun 9(1):2359), we described a novel delivery platform for RNA-based drugs using red blood cell extracellular vesicles which can efficiently deliver both small and large RNAs to solid and liquid tumours. Our RBCEVs platform features exceptional merits over conventional RNA delivery methods in biosafety, biocompatibility, efficiency, accessibility, and cost effectiveness.
Insights
Researchers developed a novel red blood cell extracellular vesicle (RBCEV) platform for efficient RNA drug delivery. This platform offers superior biosafety, biocompatibility, and cost-effectiveness for treating solid and liquid tumors.
Area of Science:
- Biotechnology
- Drug Delivery Systems
- Therapeutics
Background:
- RNA-based therapeutics face significant delivery challenges.
- Effective delivery is crucial for therapeutic efficacy.
- Current methods have limitations in safety and efficiency.
Purpose of the Study:
- To introduce a novel RNA delivery platform.
- To evaluate the efficacy of red blood cell extracellular vesicles (RBCEVs) for RNA delivery.
- To compare RBCEVs with conventional RNA delivery methods.
Main Methods:
- Utilized red blood cell extracellular vesicles (RBCEVs) as a drug delivery platform.
- Tested RBCEVs for the delivery of both small and large RNA molecules.
- Administered RBCEVs to models of solid and liquid tumors.
Main Results:
- RBCEVs demonstrated efficient delivery of RNA to both solid and liquid tumors.
- The RBCEV platform showed high biosafety and biocompatibility.
- RBCEVs proved to be an accessible and cost-effective delivery solution.
Conclusions:
- Red blood cell extracellular vesicles represent a promising platform for RNA-based therapeutics.
- RBCEVs overcome key challenges in RNA delivery.
- This novel platform offers significant advantages over existing methods.
Related Concept Videos
Electron Carriers
Over the many stages of cellular respiration, glucose breaks down into carbon dioxide and water. Electron carriers pick up electrons lost by glucose in these reactions, temporarily storing and releasing them into the electron...
Carrier Transport
Drift Current:
The drift of charge carriers is started by an external electric field (E). Charged particles, such as electrons and holes, experience an acceleration between collisions with lattice atoms. For electrons, this results in a drift velocity (vd) given by:
Cardiovascular Drugs: Classification based on Therapeutic Indications
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Carrier Generation and Recombination
This process is given by the generation rate G and is efficient due to the conservation of momentum between the valence band maximum and conduction band minimum.
Indirect generation involves an...
The ADP/ATP Carrier Protein

